Effect of soy isoflavone supplementation on markers of oxidative stress in men and women.
Dietary intake of soy has been linked with decreased cancer risk, and the active compounds in soy that have been identified include the isoflavones genistein and daidzein. Since these compounds have antioxidant properties, we examined levels of oxidative damage in blood of six women and six men before and during soy supplementation using Novasoy tablets. Blood samples were obtained at weekly intervals for 3 weeks from the women taking 50-mg isoflavones once daily and the men taking 50-mg isoflavones twice daily. Plasma levels of genistein and daidzein increased after supplementation with maximal levels occurring at 2 weeks for the women while levels in men kept increasing over the 3 weeks of study. There was wide variation between individuals in the levels of isoflavones achieved. Mean levels of 5-hydroxymethyl-2'-deoxyuridine (5-OHmdU) in DNA from nucleated blood cells decreased after 1 week of supplementation in the women, with a decrease of 47% in mean 5-OHmdU levels after 3 weeks. In men, mean 5-OHmdU levels did not decrease until after 3 weeks of supplementation, at which there was 61% decrease. Mean plasma levels of 8-isoprostanes were not changed appreciably in either men or women. These pilot results suggest that soy isoflavone supplementation decreases levels of oxidative DNA damage in humans, and this may be a mechanism behind the cancer-preventive effects of soy isoflavones.
Djuric
Z
Z
Barbara Ann Karmanos Cancer Institute, 110 East Warren, Detroit, MI 48201, USA. djuricz@karmanos.org
Chen
G
G
Doerge
D R
DR
Heilbrun
L K
LK
Kucuk
O
O
D000328:Adult; D000970:Antineoplastic Agents / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D004249:DNA Damage; D019587:Dietary Supplements; D015237:Dinoprost / Q000031:analogs & derivatives / Q000097:blood; D004968:Estrogens, Non-Steroidal / Q000493:pharmacokinetics; D028441:F2-Isoprostanes; D005260:Female; D019833:Genistein / Q000493:pharmacokinetics; D006801:Humans; D007124:Immunoenzyme Techniques; D007529:Isoflavones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D012737:Sex Factors; D013025:Glycine max / Q000627:therapeutic use*; D013936:Thymidine / Q000031:analogs & derivatives / Q000097:blood; D013997:Time Factors
D000970:Antineoplastic Agents; D004968:Estrogens, Non-Steroidal; D028441:F2-Isoprostanes; D007529:Isoflavones; D010936:Plant Extracts; C075750:8-epi-prostaglandin F2alpha; C061518:5-hydroperoxymethyl-2'-deoxyuridine; C004742:daidzein; D015237:Dinoprost; D019833:Genistein; D013936:Thymidine